Announced Wed, 15 Jul · 16:21 IST
Semaglutide scale-up impurity delays FY27 supply, no recall
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹1229.90
prior close
₹1227.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.3+0.2+0.1-1.6-0.7-2.0-4.0-4.9-6.5————
Up moveDown movePending
AI summary
Dr. Reddy's found an impurity out of spec during scale-up validation of Semaglutide API at its facility. Commercial supply to partner OneSource will halt until late October or early November 2026. Volume target revised to 6-7 million pens for Q3-Q4 FY27, down from the earlier 12 million annual goal. No patient safety issue and no recall required. Possible inventory write-down at OneSource acknowledged. Backup API supplier about a year away. No supply penalties expected.
Likely market impact
Near-term supply gap and lower FY27 Semaglutide volumes versus prior guidance. No recall or patient safety impact. Likely inventory write-down.